8 plant-based ingredients with peer-reviewed research on blood sugar, insulin sensitivity, and glucose metabolism.
Berberine activates AMPK (adenosine monophosphate kinase) — the cellular energy sensor that regulates glucose uptake and insulin sensitivity. A landmark head-to-head RCT (Zhang et al., JCEM, 2008, PMID: 18303104) showed Berberine reduced fasting blood glucose by 20%, post-meal glucose by 26%, and HbA1c by 1.5 points over 3 months — results statistically comparable to Metformin. A meta-analysis of 27 RCTs confirmed Berberine significantly reduces both fasting and post-prandial blood glucose. Unlike Metformin, Berberine also reduces LDL cholesterol and triglycerides, providing cardiovascular benefits alongside glucose regulation.
Bitter Melon (Momordica charantia) contains three active glucose-regulating compounds: charantin (steroidal saponin that lowers blood glucose), polypeptide-P (insulin-like peptide for direct cellular glucose uptake), and vicine (glycoside with hypoglycaemic activity). It also inhibits hepatic glucose-producing enzymes (glucose-6-phosphatase and fructose-1,6-bisphosphatase), reducing the liver's contribution to fasting blood sugar. Fuangchan et al. (Journal of Ethnopharmacology, 2011, PMID: 21211558) confirmed Bitter Melon significantly reduced HbA1c in newly diagnosed Type 2 diabetes patients.
Cinnamon's MHCP (methylhydroxychalcone polymer) activates insulin receptor tyrosine kinase, improving insulin receptor responsiveness. Khan et al. (Diabetes Care, 2003, PMID: 14633804) found 1g-6g/day of cinnamon reduced fasting blood glucose by 18-29%, triglycerides by 23-30%, and LDL by 7-27% over 40 days. Cinnamon also inhibits alpha-glucosidase — the enzyme that digests carbohydrates in the intestine — slowing glucose release after meals and flattening post-meal blood sugar spikes. These improvements persisted 20 days after stopping supplementation, suggesting lasting metabolic changes.
Gymnema Sylvestre's gymnemic acids work through two distinct mechanisms: blocking sweet taste receptors on the tongue (reducing the sensory reward of sugar and naturally diminishing cravings), and blocking glucose absorption receptors in the intestinal lining (reducing dietary sugar absorption into the bloodstream). In the pancreas, Gymnema stimulates insulin secretion and may regenerate beta cells. Shanmugasundaram et al. (Journal of Ethnopharmacology, 1990) confirmed 400mg/day reduced blood glucose by 29% and allowed 50% insulin dosage reduction in Type 2 diabetics over 18-24 months.
Inulin is a natural prebiotic fructan that selectively feeds beneficial gut bacteria — particularly Bifidobacterium and Lactobacillus species whose populations are directly correlated with healthy blood sugar regulation. Research establishes that individuals with Type 2 diabetes have significantly altered gut microbiome compositions that worsen insulin resistance. Inulin restores this microbial balance while also slowing gastric emptying — physically reducing the rate at which dietary carbohydrates release as blood glucose. This dual mechanism (microbiome support + mechanical glucose modulation) addresses blood sugar from an angle no other ingredient in GlycoFree targets.
Banaba's corosolic acid directly activates GLUT4 glucose transporter translocation — the process by which glucose transporters move to the cell surface to absorb blood glucose. Unlike insulin-sensitising approaches that work upstream of GLUT4, corosolic acid works directly at the transporter level, providing glucose uptake support regardless of insulin sensitivity status. This is particularly valuable for individuals with advanced insulin resistance who respond less to upstream sensitising approaches. Banaba also inhibits intestinal alpha-glucosidase, complementing Gymnema's absorption reduction.
ALA is unique among antioxidants because it dissolves in both fat and water — allowing it to protect all cellular compartments simultaneously. Chronic hyperglycaemia generates reactive oxygen species that damage insulin-signalling proteins, creating a destructive cycle of oxidative stress and worsening insulin resistance. ALA interrupts this cycle, protecting the insulin-signalling machinery that every other GlycoFree ingredient is trying to improve. ALA also regenerates vitamins C and E and glutathione, amplifying total antioxidant defence throughout the body. German clinical guidelines recognise ALA as a treatment for diabetic peripheral neuropathy at therapeutic doses.
Chromium functions as a component of chromodulin — the oligopeptide that amplifies insulin receptor tyrosine kinase activity by up to 8-fold. Without adequate chromium, insulin receptors cannot function at full efficiency even when insulin levels are normal. Chromium Picolinate has up to 4 times the bioavailability of chromium chloride. Anderson et al. (Diabetes, 1997) confirmed 1,000mcg/day Chromium Picolinate significantly reduced HbA1c (8.5 to 7.5%), fasting blood glucose (190 to 128 mg/dL), and fasting insulin in Type 2 diabetes patients over 4 months.